Cantor Fitzgerald Maintains a Hold on Pfizer (PFE)

Pfizer Inc. (NYSE:PFE) is one of the best medical stocks to buy now. In a report released on September 29, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Pfizer Inc. (NYSE:PFE) and set a price target of $24.00.

In other news, Pfizer Inc. (NYSE:PFE) announced on September 30 the signing of a historic agreement with the Trump Administration ensuring that US patients pay lower prices for their prescription medicines while bolstering the country’s role as the global leader in biopharmaceutical innovation.

Management reported that in response to the four points covered in the President’s July 31st letter, Pfizer Inc. (NYSE:PFE) has “voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets”.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.